drugset / Trial / NCT04581772

A Study to Evaluate the Bioavailability and Safety of DNL343 in Healthy Volunteers

NCT04581772

Phase 1 Completed 31 enrolled Denali Therapeutics Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This is a Phase 1 relative bioavailability study carried out in approximately 24 healthy male subjects and healthy female subjects of non childbearing potential to investigate the effects of formulation and food on the safety, tolerability, and pharmacokinetics (PK) of DNL343.

Timeline

Start
2020-12-23
Primary completion
2021-06-04
Completion
2021-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject EVETIFATOR Small molecule Oral

Indications

No indication recorded.